QI
CLVS

QS Investors’s Clovis Oncology, Inc. CLVS Stock Holding History

QS Investors’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-806
Closed -$43K – 1984
2018
Q1 		$43K Hold
806
– – ﹤0.01% 1495
2017
Q4 		$55K Hold
806
– – ﹤0.01% 1470
2017
Q3 		$66K Hold
806
– – ﹤0.01% 1468
2017
Q2 		$75K Buy
806
+6
+0.8% +$367 ﹤0.01% 1435
2017
Q1 		$51K Buy
+800
New +$48.6K ﹤0.01% 1512

Other funds holding CLVS

PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

QS Investors's CLVS Position: Q2 2018 in Review

QS Investors sold out of Clovis Oncology, Inc. (CLVS) in Q2 2018, closing a stake of 806 shares — an estimated $43K sold.

QS Investors first reported a position in CLVS in Q1 2017 and held it in 5 quarters. The position peaked at $75K in Q2 2017. 210 funds tracked by Wall St. Rank hold CLVS as of Q2 2018.

  • QS Investors reported no remaining Clovis Oncology, Inc. position as of Q2 2018 after selling out during the quarter.
  • QS Investors sold 806 Clovis Oncology, Inc. shares in Q2 2018, an estimated $43K.
  • QS Investors first reported a position in Clovis Oncology, Inc. in Q1 2017 and held it in 5 quarters.
  • QS Investors's Clovis Oncology, Inc. position peaked at $75K in Q2 2017.
  • 210 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2018.

Based on QS Investors's 13F filing for Q2 2018, filed 14 Aug 2018.